AI in Healthcare

Today's Stories

1. 1

   Gilead's Nucleai AI Deal: Oncology Bet Under Scrutiny

   Gilead Sciences (GILD) has announced an oncology AI deal with Nucleai, a move aimed at strengthening its cancer drug pipeline. The deal raises questions about whether Gilead's current valuation is justified, as the company seeks to leverage AI to improve its oncology portfolio and compete more effectively.

   Investors will be watching whether the Nucleai partnership delivers tangible results in drug development, and how this affects Gilead's financial performance and stock valuation.

2. 2

   No-Code AI Shows Promise for Bone Fracture Detection

   Researchers used Google Cloud Vertex AI to build a no-code AutoML model that classifies bone X-rays as fractured or non-fractured, achieving initial results on a mixed public dataset. This proof-of-concept demonstrates that non-experts can potentially create AI diagnostic tools, which could help expand access to medical imaging analysis. However, it is a preliminary step, not a ready-to-use clinical tool.

   Further validation on larger, more diverse datasets is needed before such models can be considered for real-world clinical use.

3. 3

   BMS taps Chai Discovery's AI for antibody design

   Bristol Myers Squibb (BMS) is partnering with Chai Discovery to use its generative AI for antibody design across BMS's portfolio. The collaboration is announced, though specific financial terms are not disclosed. This marks a significant adoption of generative AI in drug discovery, potentially accelerating the design of antibodies, which are key components in many modern therapies. It underscores the growing role of AI in pharmaceutical R&D.

   How this partnership may influence BMS's pipeline and whether it signals broader industry adoption of AI-driven drug design. The specific antibodies or therapeutic areas targeted are not yet specified.

4. 4

   AI doesn't deny care, but shapes review, says expert

   UnitedHealth Group CFO Wayne DeVeydt said at the company's Q2 earnings call in July that AI does not determine whether care is approved or denied. Cigna and Aetna have echoed that AI is never used to deny claims, but insurers still invest billions in AI for administrative tasks like prior authorizations and claims processing. Stacie Sutter from Ensemble Health Partners says payers' claims are technically true—AI doesn't click deny—but it routes which cases go to a clinician and in what condition. This creates an information asymmetry: providers don't know what the AI looks for, since payers often treat that as proprietary, forcing them to invest more time and resources upfront to avoid denials or delays.

   Sutter calls for transparency, urging payers to share approval rates, denial rates, and outcomes by AI-routed vs. non-routed requests, broken down by service type and specialty. Ensemble has achieved a 92% success rate with touchless prior authorizations for radiology cases with a national payer, but scaling beyond that may require payer engagement and robust systems.

5. 5

   Novo Nordisk names AWS as AI partner in drug discovery push

   Novo Nordisk has entered a strategic partnership with Amazon Web Services, making AWS its preferred cloud provider and strategic AI partner. The two companies have also launched a co-innovation hub in London where AWS engineers and AI specialists will work directly with Novo Nordisk's research teams. The collaboration aims to accelerate drug discovery by using AI services like Amazon Bio Discovery and Amazon Bedrock to analyze complex scientific data and identify potential drug targets. It builds on an existing relationship that Novo Nordisk says has already cut clinical documentation time and boosted productivity for more than 25,000 employees.

   The companies did not disclose financial terms or quantified targets for research savings or timelines, so the near-term impact on earnings is unclear. A key question is whether AI can meaningfully speed up drug development, since experimental medicines must still prove safety and efficacy in clinical trials.

6. 6

   Gilead Teams with Nucleai on AI Tissue Analytics for ADC Programs

   Nucleai announced an ongoing translational research collaboration with Gilead Sciences, using AI-driven tissue analytics on large H&E and IHC slide datasets to support Gilead’s global antibody-drug conjugate clinical development programs across multiple oncology indications. The work has already produced candidate spatial biomarkers and fresh biological insights. This collaboration supports Gilead’s efforts to build a credible second growth pillar in oncology beyond its HIV cash flows. It aims to sharpen biomarker selection for current and future antibody-drug conjugates, and could help standardize biomarker assessment and better link tumor biology to clinical outcomes in precision oncology.

   Gilead’s near-term focus remains on Trodelvy’s first-line breast cancer rollout and on pricing and policy pressure in HIV. The Nucleai work plugs into the ambition to make Trodelvy a more central oncology asset, but it does not remove execution risk or market access challenges.